Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print October 1, 2001, 10.1148/radiol.2212010381
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2212010381v1
221/2/508    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marom, E. M.
Right arrow Articles by McAdams, H. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marom, E. M.
Right arrow Articles by McAdams, H. P.
(Radiology. 2001;221:508-514.)
© RSNA, 2001

Thoracic Imaging

Reperfusion Edema after Lung Transplantation: Effect of Daclizumab1

Edith M. Marom, MD, Yo Won Choi, MD, Scott M. Palmer, MD, MHS, David M. DeLong, PhD, Mark D. Stuart, BS and H. Page McAdams, MD

1 From the Departments of Radiology (E.M.M., D.M.D., H.P.M.) and Medicine (S.M.P., M.D.S.), Duke University Medical Center, Box 3808, Durham, NC 27710; and Department of Radiology, Hanyang University Hospital, Seoul, Korea (Y.W.C.). Received January 29, 2001; revision requested March 12; revision received April 4; accepted May 2. Address correspondence to E.M.M. (e-mail: marom001@mc.duke.edu).

PURPOSE: To determine if daclizumab, an interleukin-2 antagonist, reduced the severity of reperfusion edema in lung transplant recipients.

MATERIALS AND METHODS: Eighty-five patients who were to undergo 86 consecutive lung transplants were included; 43 (50%) received daclizumab in addition to conventional immunosuppression. Patients were assigned to one of the following groups: control, right allograft; control, left allograft; daclizumab treated, right allograft; daclizumab treated, left allograft. Radiographs obtained in the first 5 postoperative days were evaluated for degree of edema. Mean daily edema scores and curves for control and daclizumab-treated groups were compared. Differences in survival at 1, 3, 6, and 12 months after transplantation, days of mechanical ventilation, and the ratio of arterial oxygenation to inspired oxygen level at 1, 3, and 5 days after transplantation were also compared.

RESULTS: Mean daily edema scores, edema curves, survival, days of mechanical ventilation, and ratio of arterial oxygenation to inspired oxygen level at 1 and 3 days after transplantation did not significantly differ between daclizumab-treated and control groups. A trend toward improved survival in the daclizumab-treated group was noted.

CONCLUSION: Daclizumab had no effect on the radiographic or immediate clinical manifestations of reperfusion edema in lung transplant recipients. Additional follow-up is needed to determine if daclizumab offers any long-term benefit in terms of reduced rejection rates or survival.

Index terms: Lung, edema, 60.458, 60.711 • Lung, effects of drugs on • Lung, transplantation, 60.711






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 2001 by the Radiological Society of North America.